10-Q: PROCEPT BioRobotics Q3 2025: Revenue Soars, Losses Persist

PROCEPT BioRobotics reported a 43% revenue increase to $83.3 million in Q3 2025, driven by strong U.S. sales, though net losses continued at $21.4 million.

Summary

• Revenue for the three months ended September 30, 2025, increased by 43% to $83.3 million, up from $58.4 million in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, grew by 48% to $231.7 million, compared to $156.3 million in the prior year.
• Net loss for Q3 2025 was $(21.4) million, a slight increase from $(21.0) million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved to $(65.7) million, down from $(72.6) million in the prior year.
• Gross margin increased to 65% for both the three and nine months ended September 30, 2025, up from 63% and 60% respectively in 2024.
• Operating expenses rose, with Research and Development increasing by 9% in Q3 2025 to $18.2 million and Selling, General and Administrative expenses increasing by 38% to $59.0 million.
• As of September 30, 2025, the company had an installed base of 835 AquaBeam and HYDROS Robotic Systems globally, including 653 in the United States.
• Cash and cash equivalents stood at $294.3 million as of September 30, 2025, a decrease from $333.7 million at December 31, 2024.
• The former CEO retired on September 1, 2025, resulting in $3.7 million in compensation expense due to accelerated stock-based awards and cash severance.

Sentiment

Score: 7

Explanation: The company exhibits strong revenue growth and improving gross margins, indicating successful market penetration and operational efficiency. The reduction in net loss for the nine-month period is also positive. However, the company continues to incur significant net losses and burn cash, and acknowledges potential future capital raises, which temper the overall positive sentiment. The management change is noted but does not appear to be a negative factor for future operations.

Positives

• Strong revenue growth of 43% for Q3 2025 and 48% for the nine months ended September 30, 2025, indicating increasing market adoption.
• Gross margin improved to 65% for both the three and nine months ended September 30, 2025, driven by increased unit sales and higher average selling prices.
• Net loss for the nine-month period decreased to $(65.7) million from $(72.6) million in the prior year, showing progress towards profitability.
• The global installed base of robotic systems grew to 835, with 653 in the United States, demonstrating successful market penetration.
• Favorable Medicare coverage decisions and growing commercial payor coverage for Aquablation therapy are acting as catalysts for hospital adoption and utilization.
• The company received FDA 510(k) clearance for its next-generation HYDROS Robotic System on August 20, 2024.
• The company was in compliance with all debt covenants as of September 30, 2025.

Negatives

• The company continues to incur net losses, reporting $(21.4) million for Q3 2025 and $(65.7) million for the nine months ended September 30, 2025.
• Operating expenses increased significantly, with Selling, General and Administrative expenses rising 38% in Q3 2025 and 39% for the nine months, impacting profitability.
• Cash and cash equivalents decreased from $333.7 million at December 31, 2024, to $294.3 million at September 30, 2025, indicating continued cash burn from operations.
• The retirement of the former CEO resulted in a $3.7 million compensation expense in Q3 2025.

Risks

• The company's operating performance is significantly impacted by the degree and rate of market acceptance of its products and Aquablation therapy.
• Revenue generation depends heavily on the availability of sufficient reimbursement from third-party payors (federal Medicare, state Medicaid, and private health insurance plans).
• Operating in a very competitive and rapidly changing environment poses risks from new competitors and evolving technologies.
• Future growth is dependent on the ability to obtain and maintain regulatory approvals for products and technologies.
• The commercial success and market acceptance of products are not guaranteed.
• The sufficiency of cash, cash equivalents, and short-term investments to meet future capital requirements is an ongoing concern, potentially requiring additional financing.
• Costs associated with any product recall, regulatory or government action, or other litigation could adversely affect the business.
• The costs of attaining, defending, and enforcing intellectual property rights are significant and ongoing.
• The emergence of competing technologies or other adverse market developments could negatively impact the business.
• Actual results may differ materially and adversely from forward-looking statements due to known and unknown risks, uncertainties, and assumptions.

Future Outlook

The company anticipates continued revenue growth in absolute dollars, driven by increased adoption of Aquablation therapy and higher system utilization. Gross margin is expected to improve over the long term as production volumes increase and fixed manufacturing overhead costs are spread across more units. Research and development (R&D) and Selling, General and Administrative (SG&A) expenses are projected to increase in absolute dollars as the company invests in product enhancements and commercial expansion, but are expected to decrease as a percentage of revenue over time. Management believes that existing cash and cash equivalents, combined with anticipated revenue, will be sufficient to fund operations for at least the next twelve months.

Management Comments

• "We believe that Aquablation therapy represents a paradigm shift in the surgical treatment of BPH by addressing compromises associated with alternative surgical interventions."
• "We designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that is independent of prostate size and shape, and delivers resection independent of surgeon experience."
• "We believe that these favorable coverage decisions have been a catalyst for hospital adoption of our robotic systems."
• "We believe our strong body of clinical evidence and support from key societies, supplemented by the momentum from Medicare coverage, have led to favorable coverage decisions from many large commercial payors."
• "Our future growth is dependent on these continuous improvements which require significant resources and investment."

Industry Context

PROCEPT BioRobotics operates within the competitive and rapidly evolving surgical robotics market, specifically focusing on urology with its Aquablation therapy for benign prostatic hyperplasia (BPH). The company positions its robotic systems (AquaBeam and HYDROS) as a transformative solution, aiming to establish Aquablation therapy as the surgical standard of care. This strategy leverages strong clinical evidence, key opinion leader support, and favorable reimbursement policies (e.g., Medicare coverage). The company's investment in R&D, including the integration of artificial intelligence and machine learning, aligns with broader industry trends towards advanced, data-driven medical technologies and minimally invasive procedures.

Comparison to Industry Standards

• The WATER study, the company's U.S. pivotal trial, is highlighted as the only FDA pivotal study randomized against transurethral resection of prostate (TURP), which is the historical standard of care for surgical BPH treatment.
• In the WATER study, Aquablation therapy demonstrated superior safety and non-inferior efficacy compared to TURP across prostate sizes between 30 ml and 80 ml.
• Aquablation therapy showed superior efficacy in a subset of patients with prostates larger than 50 ml when compared to TURP.
• Aquablation therapy has been added to clinical guidelines of various professional associations, including the American Urological Association, indicating strong clinical acceptance and validation against established practices.

Management Changes

Legal Proceedings

• The company is not presently a party to any legal proceedings that, in management's opinion, would have a material adverse effect on the business.

Stakeholder Impact

• Shareholders: Experience potential dilution if additional equity is raised; continued net losses impact shareholder value, but strong revenue growth and gross margin improvement offer long-term potential.
• Employees: Continued investment in employee-related expenses (salaries, stock-based compensation) indicates workforce expansion and support.
• Customers (Hospitals/Urologists): Benefit from increased system availability and support, with growing adoption suggesting satisfaction with the robotic systems.
• Patients: Gain improved access to Aquablation therapy through increased system placement and expanding insurance coverage for BPH treatment.
• Creditors: Positive impact from the company's compliance with all debt covenants and the amendment of loan terms to a single principal payment at maturity.

Next Steps

• Continue to increase the direct team of capital sales representatives to drive system placement within hospitals.
• Expand the team of highly trained Aquablation representatives and clinical specialists to drive system utilization within hospitals.
• Leverage urologists' experiences to capture more surgical volumes and establish Aquablation therapy as the surgical standard of care.
• Engage in active discussions with commercial payors to establish additional positive national and regional coverage policies.
• Expand established coverage and further improve patient access to Aquablation therapy in key international markets.
• Continue developing additional and next-generation technologies to support and improve Aquablation therapy.
• Leverage treatment data and software development capabilities to integrate artificial intelligence and machine learning for computer-assisted anatomy recognition and improved treatment planning and personalization.

Key Dates

Recommendation

PROCEPT BioRobotics demonstrates robust revenue growth and improving gross margins, signaling strong market acceptance and operational efficiency for its Aquablation therapy. The reduction in the nine-month net loss is also a positive indicator. However, the company remains unprofitable and continues to consume cash, necessitating a cautious approach. The amendment of the long-term debt to a single payment in 2027 and the explicit mention of potential future capital raises introduce financial uncertainty. While the growth trajectory is compelling, the path to sustained profitability and potential dilution from future financing warrant a 'hold' recommendation. Investors should closely monitor cash burn, profitability trends, and further market penetration.

Keywords

Surgical robotics, Urology, BPH treatment, Aquablation therapy, HYDROS Robotic System, AquaBeam Robotic System, Medical devices, Prostate health, FDA clearance, Healthcare technology, Financial results, 10-Q